The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants
Open accessAbstract
Background: Respiratory syncytial virus (RSV) is a major cause of childhood medically attended respiratory infection (MARI). Methods: We conducted a randomized, double-blind, placebo-controlled phase 3 trial in 1154 preterm infants of 1 or 2 doses of suptavumab, a human monoclonal antibody that can bind and block a conserved epitope on RSV A and B subtypes, for the prevention of RSV MARI. The primary endpoint was proportion of subjects with RSV-confirmed hospitalizations or outpatient lower respiratory tract infection (LRTI). Results: There were no significant differences between primary endpoint rates (8.1%, placebo; 7.7%, 1-dose; 9.3%, 2-dose). Suptavumab prevented RSV A infections (relative risks, .38; 95% confidence interval [CI], .14–1.05 in the 1-dose group and .39 [95% CI, .14–1.07] in the 2-dose group; nominal significance of combined suptavumab group vs placebo; P = .0499), while increasing the rate of RSV B infections (relative risk 1.36 [95% CI, .73–2.56] in the 1-dose group and 1.69 [95% CI, .92–3.08] in the 2-dose group; nominal significance of combined suptavumab group vs placebo; P = .12). Sequenced RSV isolates demonstrated no suptavumab epitope changes in RSV A isolates, while all RSV B isolates had 2–amino acid substitution in the suptavumab epitope that led to loss of neutralization activity. Treatment emergent adverse events were balanced across treatment groups. Conclusions: Suptavumab did not reduce overall RSV hospitalizations or outpatient LRTI because of a newly circulating mutant strain of RSV B. Genetic variation in circulating RSV strains will continue to challenge prevention efforts. Clinical Trials Registration: NCT02325791.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kulkarni, P. S., Hurwitz, J. L., Simões, E. A. F., & Piedra, P. A. (2018) · Viral Immunology · doi:10.1089/vim.2017.0147 · Cited by 53
Self-citation
Cited by
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
Weinreich, D. M., Sivapalasingam, S., Norton, T., Ali, S., Gao, H., Bhore, R., Musser, B. J., Soo, Y., Rofail, D., Im, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035002 · Cited by 1,642
Self-citationProspective mapping of viral mutations that escape antibodies used to treat COVID-19
Starr, T. N., Greaney, A. J., Addetia, A., Hannon, W. W., Choudhary, M. C., Dingens, A. S., Li, J. Z., & Bloom, J. D. (2021) · Science · doi:10.1126/science.abf9302 · Cited by 743
“Antibodies against some other viruses can be rendered ineffective by viral mutations that are selected during treatment of infected patients ( 2 , 3 ) or that spread globally to confer resistance on entire viral clades ( 4 ).”
BackgroundThomson, E. C., Rosen, L. E., Shepherd, J. G., Spreafico, R., da Silva Filipe, A., Wojcechowskyj, J. A., Davis, C., Piccoli, L., Pascall, D. J., Dillen, J., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.037 · Cited by 606
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape
Mazur, N. I., Terstappen, J., Baral, R., Bardají, A., Beutels, P., Buchholz, U. J., Cohen, C., Crowe, J. E., Cutland, C. L., Eckert, L., et al. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00291-2 · Cited by 420
Self-citationTackling COVID-19 with neutralizing monoclonal antibodies
Corti, D., Purcell, L. A., Snell, G., & Veesler, D. (2021) · Cell · doi:10.1016/j.cell.2021.05.005 · Cited by 383
Metadata
- Authors
- Simões, E. A. F., Forleo-Neto, E., Geba, G. P., Kamal, M., Yang, F., Cicirello, H., Houghton, M. R., Rideman, R., Zhao, Q., Benvin, S. L., Hawes, A., Fuller, E. D., Wloga, E., Pizarro, J. M. N., Munoz, F. M., Rush, S. A., McLellan, J. S., Lipsich, L., Stahl, N., Yancopoulos, G. D., Weinreich, D. M., Kyratsous, C. A., & Sivapalasingam, S.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-09-08
- Volume
- 73
- Issue
- 11
- Pages
- e4400-e4408
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W3084204945
- Cited by
- 167
- References
- 1
- FWCI
- 11.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants. https://app.cochat.ai/papers/10.1093/cid/ciaa951
- The paper
- Simões, E. A. F., Forleo-Neto, E., Geba, G. P., Kamal, M., Yang, F., Cicirello, H., Houghton, M. R., Rideman, R., Zhao, Q., Benvin, S. L., Hawes, A., Fuller, E. D., Wloga, E., Pizarro, J. M. N., Munoz, F. M., Rush, S. A., McLellan, J. S., Lipsich, L., Stahl, N., . . . Sivapalasingam, S. (2021). Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaa951
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.